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Objective: The goal of this study was to investigate the impact of ovarian preservation on the survival of
women with early-stage endometrial cancer, particularly young women.
Materials and methods: A study cohort of 64 patients with histologically conﬁrmed early-stage endo-
metrial cancer was retrospectively collected from 10 member hospitals of the Taiwanese Gynecologic
Oncology Group between 1998 and 2009. Survivorship and overall survival were compared between
these two groups using a log-rank test.
Results: All patients who underwent surgery were adult women with a mean age of 40.4 ± 9.2 years
(range 24e63 years). Ovary-preserving surgery was performed in 38 (59.4%) patients who desired to
preserve their ovaries, incidentally in 19 (29.7%) patients with a preoperative diagnosis other than
endometrial carcinoma, and in seven patients (10.9%) with unknown reasons. The 5-year recurrence-free
survival rate was 98.3% with a median follow up of 44.6 months (range 1.0e126.9 months). Eight patients
required adjuvant treatment (12.5%); one patient had documented local recurrence (1.6%); and no
metachronous ovarian malignancy occurred during follow up.
Conclusion: Preservation of bilateral ovaries does not increase cancer-related mortality. A more conser-
vative approach to surgical staging may be considered in premenopausal women with early-stage
endometrial cancer without risk factors.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.t, Mackay Memorial Hospital,
ang).
bstetrics & Gynecology. PublishedIntroduction
Uterine cancer remains one of the leading causes of cancer
mortality in women worldwide. Approximately 287,100 women
developed uterine cancer with a mortality rate of 1.7 to 2.4 per
100,000 women in 2008 worldwide [1]. In Taiwan, the incidenceby Elsevier Taiwan LLC. All rights reserved.
Table 1
Patient characteristics.
Characteristics Patients with
retained ovaries
(n ¼ 64)
n %
Age, y
30 10 15.6
31e35 11 17.2
36e40 13 20.3
41e45 9 14.1
>45 21 32.8
Type of hysterectomy
TAH 35 54.7
LAVH 24 37.5
TVH 3 4.7
RH/MRH 2 3.1
Preoperative diagnosis
Endometrial carcinoma 30 46.9
Endometrial hyperplasia 22 34.4
Leiomyoma/adenomyosis 9 14.1
Uterine prolapse 3 4.6
Reasons for ovarian preservation
Young age (45 y) and/or patient's desire 38 59.4
Other preoperative diagnosisa 19 29.7
Unknown 7 10.9
Myometrial invasion
<1/2 58 90.6
1/2 6 9.4
Final histology
Endometrioid 55 85.9
Nonendometrioid 9 14.1
Histological grade
1 51 79.7
2 12 18.8
3 1 1.5
Postoperative FIGO stage (incompleteb)
Ia 38 59.4
Ib 15 23.4
Ic 4 6.3
IIa 6 9.4
IIb 1 1.5
a Diagnosis that does not require oophorectomy and incidental ovarian
preservation.
b Unevaluated areas, such as both adnexae, or lymph node status were considered
negative. FIGO¼ International Federation of Gynecology and Obstetrics;
LAVH ¼ laparoscopy assisted vaginal hysterectomy; MRH ¼ modiﬁed radical hys-
terectomy; RH ¼ radical hysterectomy; TAH ¼ total abdominal hysterectomy;
TVH ¼ total vaginal hysterectomy.
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The primary treatment for early-stage endometrial cancer involves
hysterectomy and bilateral salpingo-oophorectomy (BSO) [3]. The
BSO procedure aims to exclude occult ovarian metastases and
decrease estrogen production; given that endometrial cancer is an
estrogen-responsive disease. However, ever since the 1988 Inter-
national Federation of Gynecology and Obstetrics (FIGO) guidelines
for endometrial cancer staging [4], there has been controversy
regarding the necessity of aggressive surgical staging, including
BSO and lymphadenectomy, particularly in young women with
early-stage disease. Traditionally, endometrial cancer has been
considered a disease of postmenopausal womenwith a median age
of 52e54 years [2]. However, a recent study has shown that up to
14% of women with endometrial cancer are premenopausal [5]. In
Taiwan, > 30% of cases occur in premenopausal patients and 10% in
women under the age of 40 years [2]. The immediate consequence
of the BSO procedure leads to surgical menopause in youngwomen,
leading to undesired climacteric symptoms, particularly hot
ﬂushes, sleep disorders, and long-term effects, as well as long-term
risks to cardiovascular and bone health [3]. Nevertheless, the BSO
procedure may not be necessary in women with early-stage
endometrial carcinoma due to the relatively low incidence of
ovarian metastases. Only ~5% of these women have ovarian me-
tastases [6,7]. The prognosis for endometrial carcinoma in pre-
menopausal women tends to be favorable, with a 5-year survival
rate > 90% in early-stage disease [8]. Ali-Fehmi et al [9] suggested
that early-stage, well-differentiated endometrial cancer is most
commonly encountered in young patients. Moreover, Lee et al [10]
reported that the risk of a coexisting malignancy is negligible in
patients with minimal preoperative risk factors and no intra-
operative evidence of advanced disease. Since no prospective
clinical trial is currently available on the survival outcomes of BSO
versus ovarian conservation at hysterectomy, the present study
aimed to investigate the impact of ovarian preservation on the
survival of women with early-stage endometrial cancer, particu-
larly in young women.
Materials and methods
Individual patient data of histologically conﬁrmed, early-stage
endometrial cancer (Types I and II) were retrospectively collected
from the data registry of the 10 member hospitals of the Taiwanese
Gynecologic Oncology Group (TGOG) between 1998 and 2009. A
total of 6098 patients were initially identiﬁed from the registries
during the study period, among whom, 72 patients had either
unilateral or bilateral ovarian preservation. After excluding patients
with unilateral ovarian preservation, 64 patients were included in
the ﬁnal analysis. Detailed information on the patients was care-
fully reviewed and extracted from individual medical charts. Pa-
rameters abstracted from the medical documents included age at
diagnosis, gravity and parity, preoperative diagnosis, date of diag-
nosis, reasons for preserving ovaries, date of recurrence, date of last
follow up, follow-up results for recurrence or secondary malig-
nancies, histological type, stage, grade, tumor size, lymphovascular
space involvement, lymph node metastases, depth of myometrial
invasion, and disease-free and overall survival. Evidence of recur-
rence was conﬁrmed by pathological or radiological examination.
The follow-up timewas deﬁned as the time from initial diagnosis to
the time of death or last follow up. Disease-free survival was
calculated as the number of months from cancer diagnosis to date
of recurrence or last follow up. Tumor staging was assigned in
accordance with the FIGO 1988 staging system. Stage of tumor was
assigned based on available pathological ﬁndings, and unevaluated
areas such as both adnexa and lymph node status were considered
negative for metastatic disease based on intraoperativeexamination. The research was approved by the respective Insti-
tutional Review Boards and Ethics Committees of the 10 member
hospitals of the TGOG.
Frequency was presented for categorical variables. Survival
analysis was evaluated using KaplaneMeier test, and statistical
differences in survival were compared using a log-rank test. All
reported p values corresponded to two-sided tests, and a p
value < 0.05 was considered signiﬁcant. All analyses were carried
out using SPSS version 17 software (SPSS, Chicago, IL, USA).Results
The clinicopathological proﬁles and treatment modalities of the
study cohort are listed in Table 1. More than three-ﬁfths of the
patients (67.2%) were young women < 45 years of age (mean
40.4 ± 9.2 years, range 24e63 years) at initial diagnosis. FIGO stages
IA and IB were the most common postoperative surgical stages,
which represented approximately four-ﬁfths of all patients (53/64,
83%). The most frequent preoperative diagnosis associated with
hysterectomy was endometrial carcinoma (46.9%), followed by
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myosis (14.1%), and uterine prolapse (4.6%). Only ﬁve patients un-
derwent either total vaginal hysterectomy or (modiﬁed) radical
hysterectomy, whereas the remaining 59 patients underwent total
abdominal hysterectomy or laparoscopy-assisted vaginal hyster-
ectomy. Histological diagnosis of pelvic lymph nodes was available
in 14 of the 64 patients, and all were negative for metastasis. Eight
patients with high-risk factors had adjuvant treatments without
additional bilateral adnexectomy: two with chemotherapy (2/8,
25%) and six with pelvic radiotherapy (6/8, 75%). Ovarian preser-
vation was performed predominately among young patients (45
years old), with or without patients' request among those with
preoperative diagnosis of endometrial cancer, followed by women
who were preoperatively diagnosed with benign disease and
without gross ﬁndings of adnexa (e.g., endometrial hyperplasia,
leiomyoma, or adenomyosis). The reasons for ovarian preservation
were not obvious based on the medical record review of seven
patients.
The 5-year recurrence-free survival rate was 98.3% with a me-
dian follow up of 44.6 months (range 1.0e126.9 months; Figure 1).
There was no signiﬁcant difference in disease-free survival be-
tween patients who desired ovarian preservation versus others
with incidental ovarian preservation (log-rank test, p ¼ 0.270).
Overall, one patient had documented local vaginal stump recur-
rence (1.6%), and another Stage I patient with endometrioid his-
tology had recurrence. No metachronous ovarian malignancy was
observed during follow up.
Discussion
We found a relatively low recurrence rate (1.6%) in the preser-
vation of bilateral ovaries at hysterectomy among patients withFigure 1. Disease-free survival in patearly-stage endometrial cancer. Although we do not know if the
recurrence was associated with hormonal inﬂuences due to a re-
sidual ovary or occult metastasis, the sites of recurrence offered no
evidence to support the suspicion that residual ovaries had inﬂu-
enced disease recurrence. A search of the literature revealed that
women who underwent bilateral oophorectomy before the age of
45 years may be associated with an increased risk of 67% in all-
cause mortality [11]. To avoid the short- and long-term conse-
quences of surgical menopause, there is a strong rationale for
ovarian preservation in young women. We must consider two
questions before we can answer whether saving perfectly normal
and functional ovaries without predictable risk factors is acceptable
in patients with early-stage endometrial cancer. First, we must
consider the risk of leaving occult ovarianmetastasis or a coexisting
synchronous primary tumor within the ovary. Second, we must
consider the activation of microscopic foci of residual endometrial
cancer by endogenous estrogen.
Most would agree that the risk of leaving occult ovarian
metastasis or a coexisting synchronous primary tumor within the
ovary is of primary concern. Although the incidence of coexisting
ovarian tumors has been shown to range from 5% to 29% [12e16],
these reports failed to mention whether these patients had extra-
uterine diseases. Lee et al [10] reviewed 260 patients with a mean
age of 51.8 years. These authors identiﬁed a nonendometrioid
histological subtype, intraoperative extrauterine disease, lymph
node metastases, and age as independent risk factors for adnexal
metastases in women with early stage and grade of endometrial
carcinoma [10]. They found a 7.3% coexisting malignancy rate, but
this was only 0.97% in patients without any evidence of intra-
operative gross extrauterine disease. Another study reviewed 178
cases of surgically treated patients with or without BSO, and they
suggested that ovarian preservation does not affect diseaseients with ovarian preservation.
Table 2
Characteristics of review literature.
Authors
Wright et al [5] Richter et al [24] Sun et al [25] Lee et al [26] Present study
Patient, n (ovarian preservation) 402 20 34 176 64
Age (y)  45  45  45  45 40.4 ± 9.2
Stage IaeIc IaeIc IaeIc IeII IeII
Ia (%) 64 71 90.3 59.4
Ib (%) 33 22 23.4
Ic (%) 3 7 3.4 6.3
II (%) 6.3 10.9
Grade
I (%) 79 70 75.6 79.7
II (%) 14 20 22.7 18.8
III (%) 3 10 107 1.5
Histologic type
Endometrioid (%) 100 87 97 100 85.9
Non-endometrioid (%) 13 3 14.1
5-year survival (%) 98 100 93.2 94.3 98.3
Recurrence (%) 5.0 2.3 1.6
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cancer [17]. In our study, metachronous ovarian malignancy was
not observed during follow up.
Many would suggest that the activation of microscopic foci of
residual endometrial cancer by endogenous estrogen is of clinical
signiﬁcance. However, this theoretical relation lacks not only
large-scale epidemiological association, but also clinical evidence.
Barakat et al [18] reported a prospective trial of estrogen
replacement therapy in >1200 women with endometrial cancer
conducted by the Gynecologic Oncology Group. Although the
study ended early, the absolute recurrence rate was only 2.1%
[hazard ratio (HR) 1.27, 95% conﬁdence interval (CI) 0.92e1.77].
Another large cohort study analyzed 3269 women; ovarian pres-
ervation had no effect on either cancer-speciﬁc survival (HR 0.58,
95% CI 0.14e2.44) or overall survival (HR 0.68, 95% CI 0.34e1.35).
The ﬁndings suggested that ovarian preservation in premeno-
pausal women with early-stage, low-grade endometrial cancer
might be safe and not associated with an increased risk of cancer-
related mortality [5]. In our study, favorable survival (98.3%) was
also found in patients with ovarian preservation. Comparing the
subgroup of ovarian preservation with prediagnosis known and
unknown endometrial cancer, a favorable prognosis was likely
noted in patients with unknown cancer, even if it was not statis-
tically signiﬁcant. Therefore, for patients approaching early-stage
malignancy incidentally diagnosed on hysterectomy, these
women may not need additional procedures if BSO is not per-
formed at the time of initial hysterectomy. Similar to prior studies,
there was no signiﬁcant difference in survival in our study
(Table 2), which reveals the feasibility and safety of ovarian pres-
ervation in patients with early-stage, low-grade endometrial
cancer.
The current study was limited by the inherent nature of a
hospital-based, retrospective study, and this must be borne in
mind while interpreting the data reported here. There was
missing information as well as several patients with an insufﬁ-
cient interval of follow up. Less than a 5-year disease-free interval
may not be sufﬁcient to guarantee patient safety, especially with
respect to the development of metachronous ovarian tumor.
However, there is a need to devise a more reliable predictor.
Available evidence supporting the beneﬁt of intraoperative frozen
biopsy to helpfully rule out an adnexal pathology is limited,
although its clinical value is worthy of study [19]. Furthermore,
positron emission/computed tomography advancements might
also provide a means of predicting occult metastasis [20,21].
However, several issues remain to be resolved, including the lowsensitivity of small occult lesions and its false positivity due to
physiological uptake [22,23].
The current study ﬁnds that the ovarian preservation is a
possible alternative in patients with early-stage endometrial can-
cer, and does not increase cancer-related mortality. A more con-
servative approach to surgical staging may be considered in
premenopausal women with early-stage endometrioid endome-
trial cancer. However, the performance of ovarian preservation is
highly individualized; patients who desire ovarian preservation
should receive a full explanation of the potential risks from their
physicians; and genetic tests may be necessary in patients with a
family history of related malignancies. We suggest that the pres-
ervation of bilateral ovaries is not suitable for endometrial cancer
patients with extrauterine spread at preoperative and intra-
operative assessment. These patients should also have longer than
typical follow up than those who have a BSO procedure at hyster-
ectomy, and careful intraoperative assessment of the adnexa is also
mandatory. Nevertheless, the current study is the only study to
report the experiences with the follow-up results of patients that
have undergone ovary-preserving surgery.
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